Coave Therapeutics has announced its lead gene therapy program, CoTx-10, for the treatment of retinal vascular diseases, such ...
The Foundation Fighting Blindness has allowed public open access to de-identified 4-year data from individuals participating ...
The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...
A new treatment is presented that eliminates the root cause of the disease and restores ocular surface health.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback